Tubulin acts as a master regulator, preventing Tau and alpha-synuclein from forming toxic clumps in Alzheimer's and Parkinson's.

Researchers found that tubulin can guide Tau and alpha synuclein toward healthy roles in neurons instead of forming toxic aggregates. The findings suggest boosting tubulin levels may help protect ...

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer's and ...

A new study from researchers at Mayo Clinic offers an important clue. The study suggests that a protein linked to Parkinson’s disease may play a major role in speeding up Alzheimer’s‑related brain ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ABLi will leverage the ability ...

Aplp1's bond with Lag3 on the cell's surface enables healthy brain cells to absorb traveling clumps of alpha-synuclein, leading to cell death, the researchers say. In mouse studies published in 2016 ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.